Combivent Respimat is a prescription inhaler that combines two bronchodilators, ipratropium bromide and albuterol sulfate, into a single device. It’s specifically approved for people with chronic obstructive pulmonary disease (COPD) who are already using one bronchodilator regularly but still experience airway tightening and need a second medication to control their symptoms.
How the Two Medications Work Together
The core idea behind Combivent Respimat is that it opens your airways through two completely different pathways at once. Ipratropium works by blocking a chemical messenger called acetylcholine that causes the muscles around your airways to contract. When that signal is blocked, those muscles relax and the airways widen. Albuterol takes a different route: it activates receptors on airway smooth muscle that trigger a chain reaction leading to muscle relaxation. Albuterol also reduces the release of inflammatory substances from immune cells in the airways.
Because these two drugs relax airway muscles through separate mechanisms, using them together can produce a stronger bronchodilating effect than either one alone. Clinical trials submitted to the FDA confirmed that the combination delivered through the Respimat device was at least as effective as the older CFC-based Combivent inhaler, with some measures showing slightly better lung function responses over time.
What Makes the Respimat Inhaler Different
The “Respimat” part of the name refers to the device itself, which uses soft mist technology rather than the pressurized propellant found in traditional metered-dose inhalers (MDIs). This matters more than it might seem. The mist from a Respimat moves at roughly 0.8 meters per second, while a standard MDI blasts medication out at 2 to 8 meters per second. That slower speed means less medication slams into the back of your throat and more actually reaches your lungs.
The mist also lasts longer. A Respimat spray hangs in the air for about 1.5 seconds, compared to just 0.15 to 0.36 seconds for an MDI. That gives you a wider window to inhale the dose properly. Studies measuring where the drug actually lands found that lung deposition with the Respimat reached about 57% of the delivered dose, compared to 20 to 44% with traditional inhalers. More medication in the peripheral airways, where COPD does much of its damage, and less wasted in your mouth and throat.
Another practical advantage: you don’t need to generate a fast, forceful breath to use it. The soft mist works well even at low inhalation speeds, which is particularly helpful for people with severe COPD who may struggle to inhale deeply.
Standard Dosing
The recommended dose is one inhalation four times a day. You can take additional puffs if needed, but the maximum is six inhalations in any 24-hour period. Each actuation delivers a fixed combination of ipratropium and albuterol, so there’s no need to adjust the ratio yourself.
Setting Up and Priming the Inhaler
Before the first use, you need to assemble the device and prime it. Start by pressing the safety release button and gently pulling off the clear base. Insert the medication cartridge narrow end first, then snap the base back into place until you hear it click. Once assembled, the inhaler should never be taken apart again.
Priming ensures you get a full dose on your first real puff. With the cap closed, twist the base, open the cap, point the inhaler away from your face, and press the dose release button. You should see a fine mist. Repeat this process three more times (four total sprays) and the inhaler is ready, loaded with about 120 remaining doses.
If you skip using the inhaler for more than three days, prime it once before your next dose. If it’s been more than 21 days since your last use, go through the full priming process again as if the inhaler were new.
Common Side Effects
The side effects of Combivent Respimat reflect its two active ingredients. Ipratropium can cause dry mouth, and albuterol may cause a slightly faster heartbeat, mild tremor, or headache. These effects are generally mild and tend to diminish as your body adjusts to the medication. Serious allergic reactions are rare but possible, particularly in people with known sensitivity to atropine or similar compounds.
Important Drug Interactions
Because Combivent Respimat contains two different types of bronchodilator, it carries two sets of interaction risks. The ipratropium component can amplify the effects of other anticholinergic medications, potentially worsening side effects like dry mouth, constipation, or urinary retention. The albuterol component interacts with several drug classes in ways worth knowing about.
Beta-blockers can reduce albuterol’s effectiveness and, in people with COPD or asthma, may trigger severe airway tightening. If you need a beta-blocker for a heart condition, a cardioselective version like metoprolol is the safer choice. Loop and thiazide diuretics (water pills) used alongside albuterol can drive potassium levels dangerously low, especially if the inhaler is used more than recommended. Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants can also intensify albuterol’s effects on the heart and blood pressure.
Who Should Not Use Combivent Respimat
The older formulation of Combivent (the CFC-based aerosol, now discontinued) contained soy lecithin and was contraindicated for anyone with a soy or peanut allergy. The Respimat formulation does not use the same propellant system, but you should still not use it if you have a known hypersensitivity to ipratropium, albuterol, atropine, or any of the inhaler’s inactive ingredients.
Combivent Respimat is approved only for COPD. It is not indicated for asthma, and it is not a rescue inhaler in the traditional sense. It’s designed for people whose COPD symptoms aren’t fully controlled by a single bronchodilator, adding a second mechanism of airway opening to their existing regimen.